出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/11/21 15:14:32」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis.
  • Lestz RM1, Fivush BA, Atkinson MA.
  • Pediatric nephrology (Berlin, Germany).Pediatr Nephrol.2014 Oct;29(10):2021-8. doi: 10.1007/s00467-014-2820-9. Epub 2014 May 3.
  • BACKGROUND: Higher doses of erythropoiesis-stimulating agents (ESA) have been associated with an increased risk of adverse outcomes in adults with chronic kidney disease (CKD) and end-stage kidney disease (ESRD), but to our knowledge no trials have been performed in children. We examined the associa
  • PMID 24794833
  • Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).
  • Macdougall IC1, Casadevall N2, Locatelli F3, Combe C4, London GM5, Di Paolo S6, Kribben A7, Fliser D8, Messner H9, McNeil J10, Stevens P11, Santoro A12, De Francisco AL13, Percheson P14, Potamianou A14, Foucher A14, Fife D14, Mérit V14, Vercammen E14; on Behalf of the PRIMS Study Group.
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.Nephrol Dial Transplant.2014 Sep 19. pii: gfu297. [Epub ahead of print]
  • BACKGROUND: Subcutaneous administration of Eprex® (epoetin alfa) in patients with chronic kidney disease (CKD) was contraindicated in the European Union between 2002 and 2006 after increased reports of anti-erythropoietin antibody-mediated pure red cell aplasia (PRCA). The Prospective Immunogenicit
  • PMID 25239637
  • Periodontal Status, Inflammation, and Malnutrition in Hemodialysis Patients - Is There a Link?
  • Garneata L1, Slusanschi O2, Preoteasa E3, Corbu-Stancu A4, Mircescu G5.
  • Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.J Ren Nutr.2014 Sep 10. pii: S1051-2276(14)00124-1. doi: 10.1053/j.jrn.2014.07.004. [Epub ahead of print]
  • BACKGROUND: Periodontal disease (PDD) was associated with inflammation, malnutrition, and higher mortality in hemodialysis (HD) patients.STUDY DESIGN AND OBJECTIVE: Cross-sectional observational study, aiming to assess the prevalence of PDD and the possible relationship among PDD, inflammation, and
  • PMID 25218877


  • L-カルニチン補充療法によりESA低反応性貧血の改善を認めた維持血液透析症例
  • セレスタ ギャヌ ラジャ,松本 昭英
  • 日本透析医学会雑誌 47(10), 647-651, 2014
  • … 腎性貧血は, 高用量のerythropoiesis stimulating agent (ESA) darbepoetin-alfa (DA) 60μg/週に十分な鉄剤を投与したにもかかわらず, 改善しなかった (Hb 8.5±0.73g/dL). …
  • NAID 130004701794
  • Hepatic Cyst Infection in an Autosomal Dominant Polycystic Kidney Disease Patient Diagnosed by Right Pleural Effusion
  • Ihara Katsuhito,Naito Shotaro,Yamaguchi Wakaba,Mori Yutaro,Toda Takayuki,Rai Tatemitsu,Uchida Shinichi,Sasaki Sei,Matsui Noriaki
  • Internal Medicine 53(12), 1355-1359, 2014
  • … Renal function and anemia, which had been resistant to darbepoetin treatment, also improved after the procedure. …
  • NAID 130004466363
  • 血液透析患者の腎性貧血に対するレボカルニチンの有効性
  • 樋口 輝美,石川 由美子,山崎 俊男,水野 真理,大川 恵里奈,瀬戸口 晴美,柳沢 順子,中島 詩織,安藤 英之,及川 治,井下 篤司,阿部 雅紀,上野 高浩,相馬 正義
  • 日本透析医学会雑誌 47(2), 119-127, 2014
  • … 服希望患者による介入試験であり,非ランダム化比較試験である.内服群はレボカルニチンを20mg/kg/日(最大用量1,200mg/日)を投与した.Erythropoiesis stimulating agents(ESAs)はrecombinant human erythropoietin(rHuEPO)とDarbepoetinα(DA)を使用しているため,rHuEPOとDAの比を200:1としrHuEPOの換算量とし,週あたりのESAs使用量,ESAs治療反応性の指標としてerythropoiesis resistance index(ERI)をESA doses/kg/g/dL/週として算出した.【結果】対象 …
  • NAID 130003395188


Dr. Reddy's Laboratories has launched darbepoetin alfa in India under the brand name 'Cresp' in August 2010. This is the ... Darbepoetin is produced by recombinant DNA technology in modified Chinese hamster ovary cells. It differs from ...



拡張検索darbepoetin alfa

darbepoetin alfa」